HofmannMarco Boehringer Ingelheim RCV GmbH & Co KGAustria

Scientific Director / Group Leader, OPD – Vienna Oncology Pharmacology & Disease Models (OPD) Boehringer Ingelheim Experienced Scientific Director and Group Leader with a strong track record in the pharmaceutical industry. Expertise spans biotechnology, small‑molecule drug discovery, translational life sciences, and in vitro and in vivo pharmacology, with a focus on oncology drug development. Deep experience in the profiling and development of targeted therapeutic modalities, including small molecules and T‑cell engagers. Proven leader in program and project management, driving complex research initiatives from early discovery through preclinical development. In recent years, his research group has built strong expertise around KRAS‑driven oncology assets and is actively broadening its scope toward additional target classes and therapeutic modalities, including small‑molecule profiling, targeted protein degraders, and bispecific antibodies. Holds a Dr. rer. nat. (PhD) in Biology (technical orientation) from the University of Stuttgart.